慢性髓性白血病实现无治疗缓解的前景
综述探讨慢性髓性白血病(CML)停用酪氨酸激酶抑制剂(TKI)实现无治疗缓解(TFR)的可能性。临床研究显示TFR仅限部分达到稳定深度分子学缓解(DMR)的患者,TKI治疗总时长、DMR持续时间与稳定性及停药时分子学缓解深度为显著因素,但多数预测因素仍不明确。
要点
- TFR已成为CML治疗主要目标之一,但仅部分稳定DMR患者可实现。
- TKI治疗总时长、DMR持续时间与稳定性是TFR显著相关因素。
- 停药时分子学缓解深度亦为显著因素,但多数预测因素仍不明确。
核心结论
- CML患者停用TKI实现TFR是可能的,但目前仅限于能达到稳定DMR的部分患者。
研究设计与样本
- 综述汇总多项对照与观察性临床试验,探讨CML患者TFR相关因素。
主要发现
- 多项临床研究证实TFR可行,但限于能 achieving 稳定DMR的部分CML患者。
- TKI治疗总时长、DMR持续时间与稳定性、停药时分子学缓解深度被显示为显著因素。
- 多数与成功停药相关的因素仍不明确。
局限性
- 多数与更高成功停药可能性相关的因素仍不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In addition to the best possible overall survival, discontinuation of the tyrosine kinase-inhibitor (TKI) treatment [treatment free remission (TFR)] without observing a recurrence of the disease has become a major goal of the therapy of chronic myelogenous leukemia (CML). Many clinical studies have demonstrated that TFR is possible, although for the moment limited to a fraction of the CML patients able to achieve a stable deep molecular response (DMR). The factors associated to the possibility of remaining in TFR or of losing it, have been investigated by a number of controlled and observation clinical trials and although total TKI treatment duration, DMR duration and stability and, more recently, also the depth of the molecular response obtained at the time of discontinuation have been shown to be significant elements, most of the factors associated with a higher possibility of a successful discontinuation still remain elusive and are here reviewed.
引用
- Saglio G, Gale RP. Prospects for achieving treatment-free remission in chronic myeloid leukaemia. Br J Haematol. 2020. PMID: 32057102. doi:10.1111/bjh.16506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。